Arcutis Biotherapeutics stock has produced very strong 3 year gains, yet the current market multiples screen it as overvalued and the broader valuation checks point to a mixed picture rather than a clear bargain. For investors, that raises the question of how much of Arcutis Biotherapeutics' recent success is already reflected in the US$25.14 share price.

• Over the past 3 years Arcutis Biotherapeutics has returned about 181.5%, which puts recent weakness into context and suggests expectations have already shifted a long way.
• Future revenue growth from approved and late stage dermatology treatments can support the current market value. However, any setback in clinical outcomes or slower than expected uptake may weigh heavily on what already screens as a rich multiple.
• A value score of 3 out of 6 points to a mixed read on Arcutis Biotherapeutics, with some checks flagging it as expensive and others looking more reasonable.

The issue now is whether Arcutis Biotherapeutics' fundamentals and risk profile can justify what appears to be a full valuation after such a strong multi year run.

Balance that strong 3 year move in Arcutis Biotherapeutics by scanning a hand picked list of other stocks that combine quality fundamentals with room for valuation support through the 51 high quality undervalued stocks

Has Arcutis Biotherapeutics Run Too Far on Earnings?

P/E is the key checkpoint for Arcutis Biotherapeutics because it directly ties the current share price to the earnings that support it. At around 110.8x, Arcutis Biotherapeutics trades on a P/E that is far above the broader Biotechs industry average of 17.7x and also well ahead of the peer group average of 42.2x.

The fair P/E ratio from the model is 38.4x, which already factors in the company’s sector, size and risk profile. The gap between this fair level and the current 110.8x reading suggests investors are paying a high premium for the stock relative to what the model implies would be reasonable.

On this P/E check, Arcutis Biotherapeutics stock appears overvalued compared with both its own fair multiple and sector benchmarks.

The Arcutis Biotherapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Arcutis Biotherapeutics valuation puzzle leaves off. They set out the specific assumptions on future growth, margins and earnings that would need to play out for Arcutis Biotherapeutics' stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Instead of just showing a single ratio or model output, they unpack the future it relies on so you can see whether that path is still on track.

One of the top community narratives on Arcutis Biotherapeutics: 37% undervalued

"The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks..."

Do you think there's more to the story for Arcutis Biotherapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Arcutis Biotherapeutics currently screens as overvalued on market multiples, so the burden of proof now sits with future execution rather than the starting price. The key question is whether the company can grow revenue from its dermatology portfolio fast enough, and with strong enough economics, to make the current P/E look more reasonable over time. For you as an investor, the crux is whether the rich valuation reflects durable growth in earnings or whether expectations have simply moved ahead of what the business can deliver.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.